| | | | 95% Confidence Interval | | | | | 95% Confidence Interval | | | |
|--|---------------------|-------------------|-------------------------------|------|--|----------------|-------------------|-------------------------------|------|--|--|
| Age group, medication class | Number '000 | % | from | to | Age group, medication class | Number '000 | % | from | to | | |
| | Total 25 to 79 | | | | | 25 to 79 | | | | | |
| Lipid- modifying agents, plain | 1,697.6 | 15.9* | 14.0 | 17.7 | Anti- depressants | 1,514.0 | 13.7* | 11.3 | 16.1 | | |
| Ace inhibitors, plain | 978.1 | 9.1* | 7.6 | 10.7 | Lipid- modifying agents, plain | 1,205.2 | 10.9 | 9.3 | 12.5 | | |
| Drugs for peptic ulcer and gastro- esophageal reflux disease (GERD) | 836.3 | 7.8 | 6.1 | 9.5 | Thyroid | 1,082.5 | 9.8* | 8.3 | 11.3 | | |
| Beta-blocking agents | 730.3 | 6.8* | 5.6 | 8.1 | Drugs for peptic ulcer and gastro- esophageal reflux disease (GERD) | 1,011.8 | 9.2 | 7.5 | 10.8 | | |
| Other analgesics and anti-pyretics | 677.7 | 6.3* | 5.4 | 7.3 | ACE inhibitors, plain | 659.6 | 6.0 | 4.9 | 7.1 | | |
| 25 to 44 | | | | | 25 to 44 | | | | | | |
| Anti- depressants | 190.8 ^E | 4.2* | 2.4 | 6.0 | Systemic us6.0e hormonal contraceptives | 513.1 | 11.4* | 8.5 | 14.3 | | |
| Drugs for peptic ulcer and gastro- esophageal reflux disease (GERD) | 163.9 ^E | 3.6 | 1.9 | 5.4 | Anti- depressants | 415.2 | 9.3 ^E | 6.0 | 12.5 | | |
| Adrenergics, inhalants | 89.9 ^E | 2.0 | 0.8 | 3.2 | Thyroid | 194.5 | 4.3* ^E | 2.6 | 6.1 | | |
| Lipid- modifying agents, plain | <149.2 ^T | <3.3 ^T | | | Drugs for peptic ulcer and gastro- esophageal | 119.1 | 2.7 ^E | 1.4 | 3.9 | | |

Abstract 2: Top 5 medications used, by sex, age group and medication class, household population aged 25 to 79, Canada, 2007 to 2011

Prevalence

Women

Prevalence

Men

| | | | | | reflux disease | | | | | |
|----------------------------------|--------------------|-------|------|------|---------------------|-------|------------------|------|------|--|
| | | | | | (GERD) | | | | | |
| ACE | 77.1 ^E | 1.7* | 0.9 | 2.5 | Adrenergics, | 105.3 | 2.3 ^E | 1.5 | 3.2 | |
| inhibitors, | | | | | inhalants | | | | | |
| plain | | | | | | | | | | |
| 45 to 64 | | | | | 45 to 64 | | | | | |
| Lipid- | 877.0 | 18.9* | 15.7 | 22.0 | Anti- | 846.4 | 17.2* | 14.3 | 20.2 | |
| modifying | | | | | depressants | | | | | |
| agents, plain | 477.7 | 10.2* | 7.0 | 10.7 | Linid | 562.0 | 11.5 | 0.0 | 14.2 | |
| Ace inhibitors, plain | 4//./ | 10.3* | 7.8 | 12.7 | Lipid- modifying | 563.9 | 11.5 | 8.8 | 14.2 | |
| piam | | | | | agents, plain | | | | | |
| Drugs for | 421.7 ^E | 9.1 | 5.9 | 12.2 | Thyroid | 536.7 | 10.9* | 8.5 | 13.4 | |
| peptic ulcer | 121.7 | 7.1 | 5.7 | 12.2 | Thyrota | 550.7 | 10.9 | 0.5 | 13.1 | |
| and gastro- | | | | | | | | | | |
| esophageal | | | | | | | | | | |
| reflux disease | | | | | | | | | | |
| (GERD) | | | | | | | | | | |
| Anti- | 381.9 | 8.2 | 5.6 | 10.9 | Drugs for peptic | 522.2 | 10.6 | 8.0 | 13.2 | |
| depressants | | | | | ulcer and | | | | | |
| | | | | | gastro- | | | | | |
| | | | | | esophageal | | | | | |
| | | | | | reflux disease | | | | | |
| Other | 364.7 | 7.8* | 6.1 | 9.6 | (GERD) Estrogens | 325.9 | 6.6* | 4.9 | 8.4 | |
| analgesics and | 504.7 | 7.0 | 0.1 | 9.0 | Esuogens | 525.9 | 0.0 | 4.9 | 0.4 | |
| anti-pyretics | | | | | | | | | | |
| 65 to 79 | | | | | 65 to 79 | | | | | |
| Lipid- | 738.7 | 47.9* | 42.0 | 53.7 | Lipid- | 584.7 | 35.6 | 30.6 | 40.6 | |
| modifying | | | | | modifying | | | | | |
| agents, plain | | | | | agents, plain | | | | | |
| ACE | 422.7 | 27.4* | 21.5 | 33.3 | Drugs for peptic | 370.4 | 22.5 | 17.6 | 27.4 | |
| inhibitors, | | | | | ulcer and | | | | | |
| plain | | | | | gastro- | | | | | |
| | | | | | esophageal | | | | | |
| | | | | | reflux disease | | | | | |
| D.4.11.1 | 250 7 | 02.2* | 17.0 | 20.0 | (GERD) | 251.2 | 01.4* | 16.0 | 25.0 | |
| Beta-blocking | 359.7 | 23.3* | 17.8 | 28.9 | Thyroid | 351.2 | 21.4* | 16.9 | 25.8 | |
| agents Other | 281.7 | 18.3 | 14.5 | 22.0 | ACE inhibitors, | 304.9 | 18.5 | 14.4 | 22.7 | |
| analgesics and | 201./ | 10.3 | 14.3 | 22.0 | plain | 304.9 | 10.3 | 14.4 | 22.1 | |
| anti-pyretics | | | | | Prani | | | | | |
| Drugs for | 250.7 | 16.3 | 11.5 | 21.0 | Beta-blocking | 275.3 | 16.7 | 12.7 | 20.8 | |
| peptic ulcer | 200.7 | 10.5 | 11.5 | 21.0 | agents | 2,0.0 | 10.7 | 12.7 | 20.0 | |
| and gastro- | | | | | 6 | | | | | |
| esophageal | | | | | | | | | | |
| reflux disease | | | | | | | | | | |
| (GERD) | | | | | | | | | | |
| (GERD) (GERD) ($(n \leq 0.5)$) | | | | | | | | | | |

* Significantly different from estimate for opposite sex (p<0.5)

^T if coefficient of variation exceeds 33.3%, but cell contains at least 10 records, estimate is indicated as being less than upper limit of 95% confidence interval

^E use with caution

... not applicable

Note: Respondents taking more than one drug in medication class are reflected in that class only once. **Source:** 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey, combined.